ering velpatasvir with eluxadoline. Taking these medications together may increase the plasma concentrations of velpatasvir and eluxadoline, potentially resulting in adverse events. Eluxadoline is a weak CYP3A4 inhibitor; velpatasvir is a substrate of CYP3A4. Additionally, velpatasvir is an inhibitor of the organic anion transporting polypeptides OATP1B1. Eluxadoline is an OATP1B1 substrate.
Emtricitabine; Rilpivirine; Tenofovir alafenamide: Monitor patients for tenofovir-associated adverse reactions, such as renal toxicity, in patients receiving regimens containing tenofovir alafenamide and velpatasvir due to potential increases in tenofovir serum concentrations. Tenofovir alafenamide is a substrate of the breast cancer resistance protein (BCRP),P-glycoprotein (P-gP), OATP1B1, and OATB1B3 transporters, while velpatasvir inhibits these transporters.
Emtricitabine; Rilpivirine; Tenofovir disoproxil fumarate: Monitor patients for tenofovir-associated adverse reactions, such as renal toxicity, in patients receiving regimens containing tenofovir and velpatasvir due to potential increases in tenofovir serum concentrations. Tenofovir is a substrate of the breast cancer resistance protein (BCRP) and P-glycoprotein (P-gp) transporters, while velpatasvir inhibits both BCRP and P-gp.
Emtricitabine; Tenofovir alafenamide: Monitor patients for tenofovir-associated adverse reactions, such as renal toxicity, in patients receiving regimens containing tenofovir alafenamide and velpatasvir due to potential increases in tenofovir serum concentrations. Tenofovir alafenamide is a substrate of the breast cancer resistance protein (BCRP),P-glycoprotein (P-gP), OATP1B1, and OATB1B3 transporters, while velpatasvir inhibits these transporters.
Emtricitabine; Tenofovir disoproxil fumarate: Monitor patients for tenofovir-associated adverse reactions, such as renal toxicity, in patients receiving regimens containing tenofovir and velpatasvir due to potential increases in tenofovir serum concentrations. Tenofovir is a substrate of the breast cancer resistance protein (BCRP) and P-glycoprotein (P-gp) transporters, while velpatasvir inhibits both BCRP and P-gp.
Enalapril; Felodipine: Use caution when administering velpatasvir with felodipine. Taking these drugs together may increase the plasma concentrations of velpatasvir, potentially resulting in adverse events. Velpatasvir is a substrate of the drug transporter P-glycoprotein (P-gp); felodipine is an inhibitor of P-gp.
Enzalutamide: Avoid coadministration of velpatasvir with enzalutamide due to the potential for loss of antiviral efficacy. Taking these drugs together may significantly decrease velpatasvir plasma concentrations, potentially resulting in loss of antiviral efficacy. Predictions regarding this interaction can be made based on the drugs metabolic pathways. Enzalutamide is a potent inducer of CYP3A4 and a weak inhibitor of the drug transporter P-glycoprotein (P-gp); Velpatasvir is a CYP3A4 and P-gp substrate.
Erythromycin: Use caution when administering velpatasvir with erythromycin. Taking these medications together may increase the plasma concentrations of both drugs, potentially resulting in adverse events. Both drugs are substrates and inhibitors of the drug transporter P-glycoprotein (P-gp). In addition, erythromycin is an inhibitor of the hepatic enzyme CYP3A4. Velpatasvir is a CYP3A4 substrate.
Erythromycin |
